|
|||||||
|
Fusion Protein:CLU-MYH9 |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: CLU-MYH9 | FusionPDB ID: 17454 | FusionGDB2.0 ID: 17454 | Hgene | Tgene | Gene symbol | CLU | MYH9 | Gene ID | 1191 | 4627 |
| Gene name | clusterin | myosin heavy chain 9 | |
| Synonyms | AAG4|APO-J|APOJ|CLI|CLU1|CLU2|KUB1|NA1/NA2|SGP-2|SGP2|SP-40|TRPM-2|TRPM2 | BDPLT6|DFNA17|EPSTS|FTNS|MATINS|MHA|NMHC-II-A|NMMHC-IIA|NMMHCA | |
| Cytomap | 8p21.1 | 22q12.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | clusterinaging-associated protein 4apolipoprotein Jcomplement cytolysis inhibitorcomplement lysis inhibitorcomplement-associated protein SP-40,40epididymis secretory sperm binding proteinku70-binding protein 1sulfated glycoprotein 2testosterone-r | myosin-9cellular myosin heavy chain, type Amyosin, heavy chain 9, non-musclenon-muscle myosin heavy chain 9non-muscle myosin heavy chain Anon-muscle myosin heavy chain IIanon-muscle myosin heavy polypeptide 9nonmuscle myosin heavy chain II-A | |
| Modification date | 20200327 | 20200315 | |
| UniProtAcc | Q15846 Main function of 5'-partner protein: | P35579 Main function of 5'-partner protein: FUNCTION: Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Promotes also cell motility together with S100A4 (PubMed:16707441). During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10 (PubMed:20052411). {ECO:0000250|UniProtKB:Q8VDD5, ECO:0000269|PubMed:16707441, ECO:0000269|PubMed:20052411}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000316403, ENST00000405140, ENST00000523500, ENST00000546343, ENST00000560366, | ENST00000401701, ENST00000475726, ENST00000216181, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 38 X 38 X 12=17328 | 44 X 46 X 15=30360 |
| # samples | 49 | 56 | |
| ** MAII score | log2(49/17328*10)=-5.14417958860576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(56/30360*10)=-5.76060115335786 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Fusion gene context | PubMed: CLU [Title/Abstract] AND MYH9 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: CLU [Title/Abstract] AND MYH9 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CLU(27463871)-MYH9(36723533), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | CLU-MYH9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CLU-MYH9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CLU-MYH9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CLU-MYH9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CLU-MYH9 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. CLU-MYH9 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. CLU-MYH9 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CLU | GO:0000902 | cell morphogenesis | 15857407 |
| Hgene | CLU | GO:0001774 | microglial cell activation | 15857407 |
| Hgene | CLU | GO:0017038 | protein import | 24446231 |
| Hgene | CLU | GO:0031333 | negative regulation of protein complex assembly | 22179788|23106396 |
| Hgene | CLU | GO:0031334 | positive regulation of protein complex assembly | 22179788 |
| Hgene | CLU | GO:0032760 | positive regulation of tumor necrosis factor production | 15857407 |
| Hgene | CLU | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 15857407 |
| Hgene | CLU | GO:0050821 | protein stabilization | 11123922|12176985 |
| Hgene | CLU | GO:0051131 | chaperone-mediated protein complex assembly | 17412999 |
| Hgene | CLU | GO:0051788 | response to misfolded protein | 19996109 |
| Hgene | CLU | GO:0061077 | chaperone-mediated protein folding | 11123922 |
| Hgene | CLU | GO:0061518 | microglial cell proliferation | 15857407 |
| Hgene | CLU | GO:1900221 | regulation of amyloid-beta clearance | 24446231 |
| Hgene | CLU | GO:1901214 | regulation of neuron death | 17412999 |
| Hgene | CLU | GO:1901216 | positive regulation of neuron death | 15857407 |
| Hgene | CLU | GO:1902430 | negative regulation of amyloid-beta formation | 12047389|17412999 |
| Hgene | CLU | GO:1905907 | negative regulation of amyloid fibril formation | 22179788 |
| Tgene | MYH9 | GO:0001525 | angiogenesis | 16403913 |
| Tgene | MYH9 | GO:0001778 | plasma membrane repair | 27325790 |
| Tgene | MYH9 | GO:0006509 | membrane protein ectodomain proteolysis | 16186248 |
| Tgene | MYH9 | GO:0030048 | actin filament-based movement | 12237319|15845534 |
| Tgene | MYH9 | GO:0031032 | actomyosin structure organization | 24072716 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:27463871/chr22:36723533) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across CLU (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across MYH9 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000405140 | CLU | chr8 | 27463871 | - | ENST00000216181 | MYH9 | chr22 | 36723533 | - | 7512 | 732 | 659 | 6124 | 1821 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000405140 | ENST00000216181 | CLU | chr8 | 27463871 | - | MYH9 | chr22 | 36723533 | - | 0.021101424 | 0.9788986 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for CLU-MYH9 |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
| CLU | chr8 | 27463871 | MYH9 | chr22 | 36723533 | 732 | 24 | TRLQKWLRPGWPPDREDQSILCTGES |
Top |
Potential FusionNeoAntigen Information of CLU-MYH9 in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| CLU-MYH9_27463871_36723533.msa |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| CLU-MYH9 | chr8 | 27463871 | chr22 | 36723533 | 732 | HLA-B07:12 | WPPDREDQSIL | 0.9979 | 0.5858 | 10 | 21 |
Top |
Potential FusionNeoAntigen Information of CLU-MYH9 in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of CLU-MYH9 |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
| File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
| 5546 | LRPGWPPDREDQSI | CLU | MYH9 | chr8 | 27463871 | chr22 | 36723533 | 732 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CLU-MYH9 |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
| HLA-B14:02 | 3BVN | 5546 | LRPGWPPDREDQSI | -7.15543 | -7.26883 |
| HLA-B14:02 | 3BVN | 5546 | LRPGWPPDREDQSI | -4.77435 | -5.80965 |
| HLA-B52:01 | 3W39 | 5546 | LRPGWPPDREDQSI | -6.80875 | -6.92215 |
| HLA-B52:01 | 3W39 | 5546 | LRPGWPPDREDQSI | -4.20386 | -5.23916 |
| HLA-A11:01 | 4UQ2 | 5546 | LRPGWPPDREDQSI | -7.5194 | -8.5547 |
| HLA-A11:01 | 4UQ2 | 5546 | LRPGWPPDREDQSI | -6.9601 | -7.0735 |
| HLA-A24:02 | 5HGA | 5546 | LRPGWPPDREDQSI | -7.52403 | -7.63743 |
| HLA-A24:02 | 5HGA | 5546 | LRPGWPPDREDQSI | -5.82433 | -6.85963 |
| HLA-B27:05 | 6PYJ | 5546 | LRPGWPPDREDQSI | -3.28285 | -4.31815 |
| HLA-B44:05 | 3DX8 | 5546 | LRPGWPPDREDQSI | -5.91172 | -6.94702 |
| HLA-B44:05 | 3DX8 | 5546 | LRPGWPPDREDQSI | -4.24346 | -4.35686 |
Top |
Vaccine Design for the FusionNeoAntigens of CLU-MYH9 |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| CLU-MYH9 | chr8 | 27463871 | chr22 | 36723533 | 10 | 21 | WPPDREDQSIL | GGCCGCCAGACCGAGAAGATCAATCCATCTTGT |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of CLU-MYH9 |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
| BLCA | CLU-MYH9 | chr8 | 27463871 | ENST00000405140 | chr22 | 36723533 | ENST00000216181 | TCGA-UY-A9PE-01A |
Top |
Potential target of CAR-T therapy development for CLU-MYH9 |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to CLU-MYH9 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to CLU-MYH9 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CLU | C0022660 | Kidney Failure, Acute | 6 | CTD_human |
| Hgene | CLU | C1565662 | Acute Kidney Insufficiency | 6 | CTD_human |
| Hgene | CLU | C2609414 | Acute kidney injury | 6 | CTD_human |
| Hgene | CLU | C0002395 | Alzheimer's Disease | 3 | CTD_human |
| Hgene | CLU | C0011265 | Presenile dementia | 3 | CTD_human |
| Hgene | CLU | C0022658 | Kidney Diseases | 3 | CTD_human |
| Hgene | CLU | C0276496 | Familial Alzheimer Disease (FAD) | 3 | CTD_human |
| Hgene | CLU | C0494463 | Alzheimer Disease, Late Onset | 3 | CTD_human |
| Hgene | CLU | C0546126 | Acute Confusional Senile Dementia | 3 | CTD_human |
| Hgene | CLU | C0750900 | Alzheimer's Disease, Focal Onset | 3 | CTD_human |
| Hgene | CLU | C0750901 | Alzheimer Disease, Early Onset | 3 | CTD_human |
| Hgene | CLU | C0013221 | Drug toxicity | 2 | CTD_human |
| Hgene | CLU | C0029408 | Degenerative polyarthritis | 2 | CTD_human |
| Hgene | CLU | C0041755 | Adverse reaction to drug | 2 | CTD_human |
| Hgene | CLU | C0086743 | Osteoarthrosis Deformans | 2 | CTD_human |
| Hgene | CLU | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| Hgene | CLU | C0022333 | Jacksonian Seizure | 1 | CTD_human |
| Hgene | CLU | C0024141 | Lupus Erythematosus, Systemic | 1 | CTD_human |
| Hgene | CLU | C0025202 | melanoma | 1 | CTD_human |
| Hgene | CLU | C0027686 | Pathologic Neovascularization | 1 | CTD_human |
| Hgene | CLU | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Hgene | CLU | C0036341 | Schizophrenia | 1 | PSYGENET |
| Hgene | CLU | C0036572 | Seizures | 1 | CTD_human |
| Hgene | CLU | C0087031 | Juvenile-Onset Still Disease | 1 | CTD_human |
| Hgene | CLU | C0149958 | Complex partial seizures | 1 | CTD_human |
| Hgene | CLU | C0234533 | Generalized seizures | 1 | CTD_human |
| Hgene | CLU | C0234535 | Clonic Seizures | 1 | CTD_human |
| Hgene | CLU | C0234985 | Mental deterioration | 1 | CTD_human |
| Hgene | CLU | C0242380 | Libman-Sacks Disease | 1 | CTD_human |
| Hgene | CLU | C0270824 | Visual seizure | 1 | CTD_human |
| Hgene | CLU | C0270844 | Tonic Seizures | 1 | CTD_human |
| Hgene | CLU | C0270846 | Epileptic drop attack | 1 | CTD_human |
| Hgene | CLU | C0333641 | Atrophic | 1 | CTD_human |
| Hgene | CLU | C0338656 | Impaired cognition | 1 | CTD_human |
| Hgene | CLU | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Hgene | CLU | C0422850 | Seizures, Somatosensory | 1 | CTD_human |
| Hgene | CLU | C0422852 | Seizures, Auditory | 1 | CTD_human |
| Hgene | CLU | C0422853 | Olfactory seizure | 1 | CTD_human |
| Hgene | CLU | C0422854 | Gustatory seizure | 1 | CTD_human |
| Hgene | CLU | C0422855 | Vertiginous seizure | 1 | CTD_human |
| Hgene | CLU | C0494475 | Tonic - clonic seizures | 1 | CTD_human |
| Hgene | CLU | C0751056 | Non-epileptic convulsion | 1 | CTD_human |
| Hgene | CLU | C0751110 | Single Seizure | 1 | CTD_human |
| Hgene | CLU | C0751123 | Atonic Absence Seizures | 1 | CTD_human |
| Hgene | CLU | C0751494 | Convulsive Seizures | 1 | CTD_human |
| Hgene | CLU | C0751495 | Seizures, Focal | 1 | CTD_human |
| Hgene | CLU | C0751496 | Seizures, Sensory | 1 | CTD_human |
| Hgene | CLU | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| Hgene | CLU | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| Hgene | CLU | C1270972 | Mild cognitive disorder | 1 | CTD_human |
| Hgene | CLU | C1862939 | AMYOTROPHIC LATERAL SCLEROSIS 1 | 1 | CTD_human |
| Hgene | CLU | C1862941 | Amyotrophic Lateral Sclerosis, Sporadic | 1 | CTD_human |
| Hgene | CLU | C3495559 | Juvenile arthritis | 1 | CTD_human |
| Hgene | CLU | C3495874 | Nonepileptic Seizures | 1 | CTD_human |
| Hgene | CLU | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| Hgene | CLU | C3714758 | Juvenile psoriatic arthritis | 1 | CTD_human |
| Hgene | CLU | C4048158 | Convulsions | 1 | CTD_human |
| Hgene | CLU | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Hgene | CLU | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| Hgene | CLU | C4316903 | Absence Seizures | 1 | CTD_human |
| Hgene | CLU | C4317109 | Epileptic Seizures | 1 | CTD_human |
| Hgene | CLU | C4317123 | Myoclonic Seizures | 1 | CTD_human |
| Hgene | CLU | C4505436 | Generalized Absence Seizures | 1 | CTD_human |
| Hgene | CLU | C4551993 | Amyotrophic Lateral Sclerosis, Familial | 1 | CTD_human |
| Hgene | CLU | C4552091 | Polyarthritis, Juvenile, Rheumatoid Factor Negative | 1 | CTD_human |
| Hgene | CLU | C4704862 | Polyarthritis, Juvenile, Rheumatoid Factor Positive | 1 | CTD_human |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies